We are entrepreneurs and offer our clients the opportunity to invest directly in growth companies alongside Independent Capital Group shareholders, clients and partners. We invest in innovative private early- to mid-stage Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options. Our focus is on Switzerland and EU countries.
With each investment opportunity we conduct a profound and very detailed due diligence to assess the value of a business and its associated risks. Based on our due diligence findings we decide, if we invest our private money into the deal or not. If yes, we will invite our co-investors to join us, based on the same terms and conditions. We manage our investments very actively. Therefore, there is always a 100% alignment of interest between us and our co-investors. We have a strong track record and a strong pipeline in both fields.